Taro Pharmaceutical Industries Ltd.

NYSE:TARO Rapporto sulle azioni

Cap. di mercato: US$1.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Taro Pharmaceutical Industries Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Taro Pharmaceutical Industries has a total shareholder equity of $1.8B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.2B and $369.1M respectively. Taro Pharmaceutical Industries's EBIT is $7.3M making its interest coverage ratio -0.1. It has cash and short-term investments of $879.4M.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi-0.1x
ContantiUS$879.35m
Patrimonio nettoUS$1.79b
Totale passivitàUS$369.06m
Totale attivitàUS$2.16b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Dec 12

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Aug 16

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Jun 02

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Feb 24

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Jan 24

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Oct 28

Taro Pharmaceutical hits 52-week low; down 28% YTD

Aug 15

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Jul 27

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Jul 14

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

Aug 03
We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Jan 26
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Analisi della posizione finanziaria

Passività a breve termine: TARO's short term assets ($1.3B) exceed its short term liabilities ($361.1M).

Passività a lungo termine: TARO's short term assets ($1.3B) exceed its long term liabilities ($8.0M).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: TARO is debt free.

Riduzione del debito: TARO had no debt 5 years ago.

Copertura del debito: TARO has no debt, therefore it does not need to be covered by operating cash flow.

Copertura degli interessi: TARO has no debt, therefore coverage of interest payments is not a concern.


Bilancio


Scoprire le aziende sane